4.19
Vanda Pharmaceuticals Inc stock is traded at $4.19, with a volume of 767.00K.
It is down -1.64% in the last 24 hours and down -10.47% over the past month.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
See More
Previous Close:
$4.26
Open:
$4.25
24h Volume:
767.00K
Relative Volume:
1.59
Market Cap:
$246.94M
Revenue:
$192.64M
Net Income/Loss:
$2.51M
P/E Ratio:
79.96
EPS:
0.0524
Net Cash Flow:
$12.42M
1W Performance:
-11.60%
1M Performance:
-10.47%
6M Performance:
-4.99%
1Y Performance:
-25.71%
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
Name
Vanda Pharmaceuticals Inc
Sector
Industry
Phone
202-734-3400
Address
2200 PENNSYLVANIA AVE NW, WASHINGTON
Compare VNDA with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
VNDA
Vanda Pharmaceuticals Inc
|
4.19 | 251.06M | 192.64M | 2.51M | 12.42M | 0.0524 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-31-24 | Initiated | H.C. Wainwright | Buy |
Jul-11-24 | Initiated | Cantor Fitzgerald | Overweight |
Feb-25-22 | Downgrade | Jefferies | Buy → Hold |
May-12-21 | Initiated | BofA Securities | Buy |
Jan-14-21 | Downgrade | Citigroup | Buy → Neutral |
Oct-29-20 | Upgrade | Citigroup | Neutral → Buy |
Jun-09-20 | Downgrade | Citigroup | Buy → Neutral |
Mar-16-20 | Downgrade | Oppenheimer | Perform → Underperform |
Mar-12-20 | Upgrade | Citigroup | Neutral → Buy |
Nov-07-19 | Downgrade | Citigroup | Buy → Neutral |
Aug-01-19 | Upgrade | Citigroup | Neutral → Buy |
Jul-25-19 | Downgrade | Stifel | Buy → Hold |
Dec-11-18 | Downgrade | Oppenheimer | Outperform → Perform |
Dec-04-18 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
Dec-04-18 | Reiterated | Jefferies | Buy |
Nov-08-18 | Resumed | Jefferies | Buy |
Sep-21-18 | Resumed | Oppenheimer | Outperform |
May-23-18 | Initiated | Citigroup | Buy |
Jan-19-18 | Initiated | Seaport Global Securities | Buy |
Sep-14-17 | Reiterated | Piper Jaffray | Overweight |
Jun-27-17 | Resumed | Piper Jaffray | Overweight |
May-26-17 | Initiated | H.C. Wainwright | Buy |
Apr-12-17 | Initiated | Oppenheimer | Outperform |
Nov-09-16 | Initiated | Aegis Capital | Buy |
Oct-06-16 | Resumed | Jefferies | Buy |
View All
Vanda Pharmaceuticals Inc Stock (VNDA) Latest News
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q2 2025 Earnings Call Transcript - Insider Monkey
Vanda (VNDA) Q2 Revenue Rises 4% - The Motley Fool
Vanda Pharmaceuticals Inc (VNDA) Q2 2025 Earnings Call Highlights: Revenue Growth Amid Rising ... By GuruFocus - Investing.com Canada
Vanda Pharmaceuticals Inc (VNDA) Q2 2025 Earnings Call Highlights: Revenue Growth Amid Rising Expenses - GuruFocus
Vanda Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks
Vanda Pharmaceuticals 2025 Q2 Earnings Misses Targets as Net Loss Widens 502% - AInvest
Vanda: Q2 Earnings Snapshot - Norwalk Hour
What are Vanda Pharmaceuticals Inc. company’s key revenue driversBreakout Stocks Opportunities That Work - jammulinksnews.com
Vanda Pharmaceuticals' Q2 2025: Navigating Contradictions in Bysanti, PONVORY, and DTC Strategies - AInvest
Vanda Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Vanda Pharmaceuticals Q2 2025 misses EPS and revenue forecasts - Investing.com
Vanda Pharmaceuticals: Navigating Q2 Earnings Disappointment Amid High-Stakes Pipeline Progress - AInvest
Vanda Pharmaceuticals Sees Strong Fanapt Growth Despite Rising Losses - Finimize
Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Vanda Pharmaceuticals' Q2 2025 Earnings: A Turning Point in Pipeline Execution and Commercialization - AInvest
Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results - PR Newswire
How volatile is Vanda Pharmaceuticals Inc. stock compared to the marketMarket Forecast Data Feed Backed By Experts - jammulinksnews.com
Exploring US High Growth Tech Stocks For Potential Portfolio Expansion - simplywall.st
How Vanda Pharmaceuticals Inc. stock performs during market volatilityExit Ready Momentum Stock Watchlist Expanded - metal.it
Price Channel Expanding on Vanda Pharmaceuticals Inc.’s ChartROI Boosting Trade Opportunity Calendar Published - metal.it
Bronstein, Gewirtz & Grossman, LLC Class Action Update Vanda Pharmaceuticals Inc. (VNDA), Stamps.com Inc. (STMP) & Syneos Health, Inc. (SYNH) - ACCESS Newswire
Investor Network: Vanda Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
How many analysts rate Vanda Pharmaceuticals Inc. as a “Buy”Overwhelming profit margins - jammulinksnews.com
Should I hold or sell Vanda Pharmaceuticals Inc. stock in 2025Free Trading Psychology Coaching - jammulinksnews.com
How does Vanda Pharmaceuticals Inc. generate profit in a changing economyBuild a diversified portfolio for stability - jammulinksnews.com
Why Vanda Pharmaceuticals Inc. stock attracts strong analyst attentionRapid Gain Targets - metal.it
Is Vanda Pharmaceuticals Inc. a growth stock or a value stockAchieve superior returns with professional insights - jammulinksnews.com
What institutional investors are buying Vanda Pharmaceuticals Inc. stockAchieve consistent profits with disciplined trading - jammulinksnews.com
Is Vanda Pharmaceuticals Inc. a good long term investmentRapid wealth accumulation - PrintWeekIndia
When is the best time to buy Vanda Pharmaceuticals Inc. stockPowerful profit generation - jammulinksnews.com
Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025 - Barchart.com
Vanda Pharmaceuticals Inc. Stock Analysis and ForecastSkyrocketing investment returns - jammulinksnews.com
What analysts say about Vanda Pharmaceuticals Inc. stockAccelerated capital growth - Autocar Professional
Vanda Pharmaceuticals Schedules Q2 Earnings Call: Key Financial Updates Coming July 31 - Stock Titan
What drives Vanda Pharmaceuticals Inc. stock priceMassive profits - jammulinksnews.com
Vanda Pharmaceuticals Inc Stock (VNDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):